跳至主要内容
临床试验/ACTRN12611001287921
ACTRN12611001287921尚未招募2 期

A pilot study of the impact of high-dose vitamin D supplementation on non-alcoholic steatohepatitis

Dr Matthew Kitson0 个研究点目标入组 30 人开始时间: 2011年12月15日最近更新:
适应症

试验速览

阶段
2 期
状态
尚未招募
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Treatment

入排标准

年龄范围
18 Years 至 70 Years(—)
性别
All

入选标准

  • NAFLD Activity Score of 4 or more, with a score of at least 1 point each in steatosis, lobular inflammation and hepatocyte ballooning component scores, on liver biopsy within the previous 3 months.

排除标准

  • Alcohol intake of 30g/day or greater in males and 20g/day or greater in females
  • Any contraindication to percutaneous liver biopsy
  • Presence of HBsAg+ or HCV PCR+, or any other cause of liver disease other than NASH
  • Pregnant or breast-feeding
  • Uncontrolled Type 2 Diabetes Mellitus
  • Inability to provide informed consent
  • Presence of significant cardiovascular or renal disease
  • Corrected calcium >2.60 mmol/L
  • History of nephrolithiasis or sarcoidosis
  • Current therapy with vitamin D, vitamin E, thiazolidinediones, milk thistle, hepatic enzyme inhibitors or with drugs known to cause steatohepatitis

研究者

发起方
Dr Matthew Kitson

相似试验